Polymerase proofreading-associated polyposis, caused by germline variants in the exonuclease domains of POLD1 and POLE, is a dominantly inherited rare condition characterized by oligo-adenomatous polyposis and increased risk of colorectal cancer, endometrial cancer and brain tumours. We report the first Japanese case of polymerase proofreading-associated polyposis carrying a POLD1 variant. The proband was a Japanese woman who had undergone resections of early colorectal carcinomas repeatedly and a hysterectomy with bilateral oophorectomy for endometrial cancer, all of which were diagnosed within 2Â years after the first colectomy at 49Â year old. Colonoscopic examinations demonstrated at least 14 non-cancerous polypoid lesions, some of which were histologically confirmed to be adenoma. Multigene panel sequencing identified a missense variant in POLD1 (c.1433G>A). Although her relatives did not undergo genetic testing, her father and paternal grandfather died of brain tumours at 53 and ~30Â years of age, respectively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jjco/hyaa090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Updates and Surveillance Recommendations for DNA Replication Repair Deficiency Syndromes in Children and Young Adults.
Clin Cancer Res
August 2024
Division of Haematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Replication repair deficiency (RRD) is a pan-cancer mechanism characterized by abnormalities in the DNA mismatch repair (MMR) system due to pathogenic variants in the PMS2, MSH6, MSH2, or MLH1 genes, and/or in the polymerase-proofreading genes POLE and POLD1. RRD predisposition syndromes (constitutional MMR deficiency, Lynch, and polymerase proofreading-associated polyposis) share overlapping phenotypic and biological characteristics. Moreover, cancers stemming from germline defects of one mechanism can acquire somatic defects in another, leading to complete RRD.
View Article and Find Full Text PDFCorrection: Multiple duodenal epithelial tumors in a patient with polymerase proofreading-associated polyposis in POLE variant.
Clin J Gastroenterol
June 2024
Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Multiple duodenal epithelial tumors in a patient with polymerase proofreading-associated polyposis in POLE variant.
Clin J Gastroenterol
June 2024
Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Article Synopsis
- Polymerase proofreading-associated polyposis (PPAP) is a rare genetic condition caused by mutations in the POLE and POLD1 genes, leading to an increased risk of several cancers, especially colon, duodenal, and endometrial cancers.
- A case study highlighted a 43-year-old woman whose multiple duodenal tumors and cancer history prompted genetic testing, revealing a specific mutation in the POLE gene.
- It is important for patients with multiple cancers or a family history of cancer to undergo genetic evaluation, as early detection and endoscopic treatment of duodenal tumors in those with PPAP can significantly improve outcomes.
Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases ε and δ in glioma families.
Acta Neuropathol Commun
November 2023
Department of Human Genetics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Article Synopsis
- Pathogenic variants in the POLE and POLD1 genes are linked to an inherited condition, polymerase proofreading-associated polyposis, which increases the risk of colorectal cancer and other tumors, including gliomas.
- Whole-exome sequencing of glioma patients revealed that 16% carried rare deleterious POLE/POLD1 variants, with significant features indicating defective DNA proofreading and a correlation with tumor characteristics.
- Glioblastoma patients with these variants had a notably shorter average overall survival of 21 months, and these genetic variants might also make glioma patients more responsive to immunotherapy and warrant ongoing surveillance for other cancer risks.
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1.
Genome Med
October 2023
Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Background: Germline variants affecting the proofreading activity of polymerases epsilon and delta cause a hereditary cancer and adenomatous polyposis syndrome characterized by tumors with a high mutational burden and a specific mutational spectrum. In addition to the implementation of multiple pieces of evidence for the classification of gene variants, POLE and POLD1 variant classification is particularly challenging given that non-disruptive variants affecting the proofreading activity of the corresponding polymerase are the ones associated with cancer. In response to an evident need in the field, we have developed gene-specific variant classification recommendations, based on the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) criteria, for the assessment of non-disruptive variants located in the sequence coding for the exonuclease domain of the polymerases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!